Roche’s patent halts an Amgen biosimilar debut

25/09/2015 - 2 minutes

Amgen has had great success with its Avastin biosimilar, used as an inhibitor of angiogenesis in tumor growth. However, despite smashing the phase III trials, the Amgen-Allergan partnership still has to wait until 2022 for Roche’s European Avastin patent to expire.

Amgen-logoAmgen partnered up with Dublin based Allergan (Ireland) for a comprehensive oncology biosimilars pipeline back in 2011. In a successful phase III trial for non-small cell lung cancer (NSCLC), the Amgen biosimilar showed full-efficacy equivalent to the Roche drug Avastin. However, the Amgen-Allergan duo may be over-prepared to take a slice of the Roche €6.6Bn annual Avastin revenue.

Patents for Avastin (bevacizumab) don’t expire until 2019 in the US and as far-off as 2022 in Europe. But this hasn’t stopped Amgen and Allergan’s advanced trials of their bevacizumab biosimilar (ABP 215), which aspires to be used as an angiogenesis inhibitor in up to 5 other cancer types following the NSCLC study. Bevacizumab is currently licensed under the Avastin trade name for use in colorectal cancer, 

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member